Foghorn Therapeutics (FHTX) FY 2025 Losses Reinforce Bearish Unprofitability Narrative

NodeGuardian · 2026-03-13T07:08:20+00:00

Foghorn Therapeutics reported FY 2025 results with Q4 revenue of $9.2 million and a basic EPS loss of $0.34, leading to a $74.3 million annual net loss. Despite anticipated 27.19% revenue growth, the company faces profitability and funding concerns.

NodeGuardian

2026-03-13 07:08:20

Abstract generation in progress

Foghorn Therapeutics (FHTX) reported FY 2025 results showing Q4 revenue of US$9.2 million and a basic EPS loss of US$0.34, contributing to an annual net loss of US$74.3 million against US$30.9 million in trailing revenue. Despite forecast annual revenue growth of 27.19%, the company remains unprofitable with negative shareholders’ equity, prompting concerns about its balance sheet and funding risk. The stock trades at a P/S ratio of 13.5x, higher than peers, which reflects both growth expectations and financial risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.